Publications by authors named "Y Funaki"
A 61-year-old woman, hospitalized for a persistent cough and dyspnea, had no history of bronchial asthma, but was undergoing chemotherapy for methotrexate-related lymphoproliferative disorder due to rheumatoid arthritis. Her peripheral blood eosinophil count was significantly increased, and chest CT revealed left lower lobe atelectasis and high-attenuation mucus. Bronchoscopy revealed mucous plugs and pathological examination revealed numerous eosinophils and filamentous fungi.
View Article and Find Full Text PDFArticle Synopsis
- Tocotrienols, specifically β-tocotrienols, have been studied for their ability to inhibit the proliferation and migration of airway smooth muscle (ASM) cells, which is important for understanding asthma treatment.
- The study involved treating human ASM cells with β-tocotrienol before stimulating them with PDGF-BB to see how it affected cell growth and movement, utilizing various assays to measure results.
- Findings indicate that β-tocotrienol reduces harmful RhoA activation and reactive oxygen species (ROS) production, potentially offering a new therapeutic approach for asthma by mitigating airway remodeling, although it doesn't impact certain associated signaling pathways.
Constipation causes substantial morbidity worldwide. This survey assessed constipation-related factors in Japan using the Japanese version of the Irritable Bowel Syndrome Quality of Life (IBS-QOL-J) instrument. We also examined the relationship among laxative type, Bristol Stool Form Scale (BSFS) scores, and treatment cost.
View Article and Find Full Text PDFBackground: Major randomized clinical trials have shown that biological therapy can reduce the exacerbation rate and oral corticosteroid (OCS) dosage in patients with severe eosinophilic asthma. However, data on the continuation, efficacy, and safety of biological therapy in older patients with asthma are limited. Therefore, the aim of this study was to evaluate the differences in the continuation rate, efficacy, and safety of biological therapy between older (≥ 65 years) and younger (< 65 years) patients with asthma.
View Article and Find Full Text PDFPembrolizumab is an anti-programmed cell death-1 (PD-1) antibody used to treat various cancer types. Treatments with such immune checkpoint inhibitors cause immune-related adverse events. However, airway inflammation caused by immune-related adverse events has rarely been reported.
View Article and Find Full Text PDF